-
1
Identifying factors for pembrolizumab eligibility in head and neck cancer
Published 2025-02-01Subjects: Get full text
Article -
2
Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
Published 2024-03-01Subjects: Get full text
Article